Insmed Inc (INSM): Gross Profit

Annual figures by period end, from SEC filings. For years the company left out, it is revenue minus cost of revenue, computed by TickerFacts; where both exist they agree (see each figure's source).

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$483.49M

Year ended 2025-12-31

$949.42M

Trailing 12 months to 2026-06-30

+36.5%

3-year compound annual growth

+31.2%

5-year compound annual growth

2017-12-31 Gross Profit (USD) 2025-12-31

Period ended	Gross Profit	Change YoY	Source filing
2025-12-31	$483.49M	+73.9%	2026-02-19, From 2025-01-01
2024-12-31	$277.96M	+16.0%	2026-02-19, From 2024-01-01
2023-12-31	$239.63M	+26.0%	2026-02-19, From 2023-01-01
2022-12-31	$190.23M	+31.8%	2025-02-20, From 2022-01-01
2021-12-31	$144.31M	+15.9%	2024-02-22, From 2021-01-01
2020-12-31	$124.54M	+10.9%	2023-02-23, From 2020-01-01
2019-12-31	$112.25M	n/m	2020-02-25, From 2019-01-01
2018-12-31	$7.41M	n/a	2020-02-25, From 2018-01-01
2017-12-31	$0	n/a	2020-02-25, From 2017-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Gross Profit	Change YoY
Insmed Inc (INSM)	2025-12-31	$483.49M	+73.9%
Opko Health, Inc. (OPK)	2025-12-31	$205.94M	-5.8%
TG Therapeutics, Inc. (TGTX)	2025-12-31	$515.57M	+77.5%
Organogenesis Holdings Inc. (ORGO)	2024-12-31	$366.30M	+12.1%
HUTCHMED (China) Ltd (HCM)	2025-12-31	$212.16M	-24.6%
Kiniksa Pharmaceuticals International, plc (KNSA)	2025-12-31	$599.89M	+65.6%
Supernus Pharmaceuticals, Inc. (SUPN)	2025-12-31	$644.39M	+10.4%
Amphastar Pharmaceuticals, Inc. (AMPH)	2025-12-31	$356.06M	-4.8%
Pacira BioSciences, Inc. (PCRX)	2025-12-31	$576.66M	+8.7%

Compare INSM, OPK, TGTX, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗